Characterization and clinical outcomes of low hormonal receptor positive / HER2 negative early breast cancer

被引：0
|
作者：
Karnmanee, J. [1 ]
Dajsakdipon, T. [2 ]
Sripaiboonkij, N. [3 ]
Dejthevaporn, T. [2 ]
机构：
[1] Mahidol Univ, Ramathibodi Hosp, Fac Med, Bangkok, Thailand
[2] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Med, Bangkok, Thailand
[3] Mahidol Univ, Ramathibodi Hosp, Fac Med, Ramathibodi Comprehens Canc Ctr, Bangkok, Thailand
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.240
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
299P
引用
收藏
页码：S340 / S340
页数：1
相关论文
共 50 条
  • [31] High HER2 gene amplification and clinical outcomes in localized HER2-positive breast cancer
    Reynolds, K. L.
    Sasmit, S.
    Moy, B.
    Elena, B.
    Amy, C.
    Atul, B.
    Aditya, B.
    CANCER RESEARCH, 2013, 73
  • [32] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
    Luciana de Moura Leite
    Marcelle Goldner Cesca
    Monique Celeste Tavares
    Debora Maciel Santana
    Erick Figueiredo Saldanha
    Paula Tavares Guimarães
    Daniella Dias Silva Sá
    Maria Fernanda Evangelista Simões
    Rafael Lima Viana
    Francisca Giselle Rocha
    Simone Klog Loose
    Sinara Figueiredo Silva
    Rafaela Pirolli
    Camilla Albina Zanco Fogassa
    Bruna Raphaeli Silva Mattos
    Fernando Augusto Batista Campos
    Solange Moraes Sanches
    Vladmir Cláudio Cordeiro de Lima
    Noam Falbel Pondé
    Breast Cancer Research and Treatment, 2021, 190 : 155 - 163
  • [33] Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
    Laidi, Fatna
    Bouziane, Amal
    Lakhdar, Amina
    Khabouze, Samira
    Rhrab, Brahim
    Zaoui, Fatima
    ONCOTARGETS AND THERAPY, 2014, 7 : 1285 - 1289
  • [34] Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2− negative breast cancer
    Matthew R. Kearney
    Julia E. McGuinness
    Kevin Kalinsky
    Breast Cancer Research and Treatment, 2021, 189 : 1 - 13
  • [35] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
    de Moura Leite, Luciana
    Cesca, Marcelle Goldner
    Tavares, Monique Celeste
    Santana, Debora Maciel
    Saldanha, Erick Figueiredo
    Guimaraes, Paula Tavares
    Sa, Daniella Dias Silva
    Simoes, Maria Fernanda Evangelista
    Viana, Rafael Lima
    Rocha, Francisca Giselle
    Loose, Simone Klog
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla Albina Zanco
    Mattos, Bruna Raphaeli Silva
    Campos, Fernando Augusto Batista
    Sanches, Solange Moraes
    de Lima, Vladmir Claudio Cordeiro
    Ponde, Noam Falbel
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (01) : 155 - 163
  • [36] HER2 positive breast cancer
    Gianni, Luca
    Bianchini, Giampaolo
    CANCER RESEARCH, 2023, 83 (05)
  • [37] Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
    Pegram, Mark
    Jackisch, Christian
    Johnston, Stephen R. D.
    NPJ BREAST CANCER, 2023, 9 (01)
  • [38] Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
    Mark Pegram
    Christian Jackisch
    Stephen R. D. Johnston
    npj Breast Cancer, 9
  • [39] Characteristics and clinical differences of breast cancer patients with negative or low HER2 expression
    Voutsadakis, Ioannis
    Rosso, Christopher
    CANCER RESEARCH, 2022, 82 (04)
  • [40] The Genomic Landscape of ER Positive, HER2 Negative Breast Cancer
    Ramakrishna, M.
    Martin, S.
    Campbell, P. J.
    Futreal, P. A.
    Stratton, M. R.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S132 - S132
12345